Literature DB >> 12389939

Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection.

Norihiro Furusyo1, Hisashi Nakashima, Kenichiro Kashiwagi, Norihiko Kubo, Kazuhiro Hayashida, Sadakazu Usuda, Shunji Mishiro, Seizaburo Kashiwagi, Jun Hayashi.   

Abstract

The aims of this retrospective survey were to determine the epidemiologic distribution of hepatitis B virus (HBV) genotypes and analyze the genotype-related clinical differences among Japanese patients with chronic HBV infection. The 158 surveyed patients with chronic HBV infection lived in Fukuoka and Okinawa were serially tested for serum alanine aminotransferase (ALT) and hepatitis B e antigen (HBeAg). Follow-up was for a period of 10.8 +/- 6.4 years (mean +/- SD). The HBV genotypes were determined in sera by an enzyme-linked immunosorbent assay and detection of HBV DNA in serum was done by the transcription-mediated amplification-hybridization protection assay. Genotypes B and C were found in 58 (36.7%) and 100 (63.3%) of the patients, respectively. Genotype B was predominant in Okinawa (B = 86.9%, C = 13.1%), whereas genotype C was predominant in Fukuoka (B = 5.2%, C = 94.8%). The HBeAg positivity and ALT abnormality rates at the start of the observation period were significantly higher in patients with genotype C (66.0% and 84.0%) than in patients with genotype B (34.5% and 22.4%) (P < 0.05, respectively). The annual rate of spontaneous HBeAg disappearance in patients with genotype B was much higher than in patients with genotype C (8.38% versus 2.34%, respectively). Patients with genotype C who were continuously HBeAg negative from entry had a significantly higher ALT abnormality (58.8%) than those with genotype B (19.2%) (P < 0.05). Interestingly, patients with genotype C who became HBeAg negative after treatment with interferon had a high ALT abnormality (58.8%). All patients with an ALT abnormality were positive for HBV DNA in their serum. These findings indicate that patients with HBV genotype C have more severe liver deterioration because of the delay of HBeAg disappearance and continued HBV replication after HBeAg disappearance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12389939     DOI: 10.4269/ajtmh.2002.67.151

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  5 in total

1.  Simultaneous genotyping and quantification of hepatitis B virus for genotypes B and C by real-time PCR assay.

Authors:  Yao Zhao; Xiu-Yu Zhang; Jin-Jun Guo; Ai-Zhong Zeng; Jie-Li Hu; Wen-Xiang Huang; You-Lan Shan; Ai-Long Huang
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

2.  Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients.

Authors:  Masayuki Murata; Norihiro Furusyo; Mami Unno; Eiichi Ogawa; Kazuhiro Toyoda; Hiroaki Taniai; Hachiro Ohnishi; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

3.  Hepatitis B Virus Infection among Japanese Immigrants and Descendants: The Need to Strengthen Preventive and Control Measures.

Authors:  Luiz Henrique Ferraz Demarchi; Larissa Melo Bandeira; Deborah Ledesma Taira; Marina Castilhos Souza Umaki Zardin; Mary Luizia Ibanhes; Ana Olivia Pascoto Esposito; Larissa Domingues Castilho De Arruda; Crhistinne Cavalheiro Maymone Gonçalves; Sabrina Moreira Dos Santos Weis-Torres; Gabriela Alves Cesar; Rivaldo Venâncio Da Cunha; Tayana Serpa Ortiz Tanaka; Marco Antonio Moreira Puga; Grazielli Rocha De Rezende; Roberta Barbosa Lopes; Silvia Naomi de Oliveira Uehara; João Renato Rebello Pinho; Flair Jose Carrilho; Michele Soares Gomes-Gouvêa; Ana Rita Coimbra Motta-Castro
Journal:  Viruses       Date:  2022-05-18       Impact factor: 5.818

Review 4.  Molecular characteristics and stages of chronic hepatitis B virus infection.

Authors:  Ying-Hui Shi; Chang-He Shi
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

5.  Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study.

Authors:  Norihiro Furusyo; Hiroaki Takeoka; Kazuhiro Toyoda; Masayuki Murata; Yuichi Tanabe; Eiji Kajiwara; Junya Shimono; Akihide Masumoto; Toshihiro Maruyama; Hideyuki Nomura; Makoto Nakamuta; Kazuhiro Takahashi; Shinji Shimoda; Koichi Azuma; Hironori Sakai; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.